![](/images/graphics-bg.png)
Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients
المؤلفون المشاركون
المصدر
Iranian Red Crescent Medical Journal
العدد
المجلد 12، العدد 6 (30 نوفمبر/تشرين الثاني 2010)، ص ص. 655-659، 5ص.
الناشر
تاريخ النشر
2010-11-30
دولة النشر
الإمارات العربية المتحدة
عدد الصفحات
5
التخصصات الرئيسية
الموضوعات
الملخص EN
Background : iron overload is the main cause of morbidity and mortality in patients with beta thalassemia major.
Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major.
The combined treatment with deferoxamine and defer prone could have an increased chelation efficacy and allow drug doses and toxicity to be reduced.
Methods : eighty patients with thalassemia major were randomized to receive one of the treatments : deferoxamine given in combination with defer prone and deferoxamine alone.
Changes in serum ferritin and any toxicity were determined.
Results : after one year, the mean serum ferritin (± SD) in deferoxamine alone group decreased from 2945 (± 591) ng / ml to 2,451 (± 352) ng / ml (p < 0.001).
In the group treat with deferoxamine and defer prone, a dramatically decline was noticed from 2986 (± 612) ng / ml to 2,082 (± 221) ng / ml (p < 0.001).
A significant improvement was observed after 6 months of combination therapy.
The main side-effects were skin reactions (deferoxamine alone), nausea and arthralgia (combined therapy).
Conclusion : combination therapy is a practical and effective procedure to decrease severe iron overload in patients with beta thalassemia major.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Tamaddoni, A.& Ramizani, M. S.. 2010. Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients. Iranian Red Crescent Medical Journal،Vol. 12, no. 6, pp.655-659.
https://search.emarefa.net/detail/BIM-252118
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Tamaddoni, A.& Ramizani, M. S.. Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients. Iranian Red Crescent Medical Journal Vol. 12, no. 6 (Nov. 2010), pp.655-659.
https://search.emarefa.net/detail/BIM-252118
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Tamaddoni, A.& Ramizani, M. S.. Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients. Iranian Red Crescent Medical Journal. 2010. Vol. 12, no. 6, pp.655-659.
https://search.emarefa.net/detail/BIM-252118
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 658-659
رقم السجل
BIM-252118
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)